NASDAQ:BNTC Benitec Biopharma (BNTC) Stock Price, News & Analysis $9.02 +0.14 (+1.58%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$8.65▼$9.0250-Day Range$7.26▼$10.4152-Week Range$2.69▼$10.88Volume9,037 shsAverage Volume48,684 shsMarket Capitalization$84.50 millionP/E RatioN/ADividend YieldN/APrice Target$19.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Benitec Biopharma alerts: Email Address Benitec Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.25 Rating ScoreUpside/Downside118.0% Upside$19.67 Price TargetShort InterestHealthy0.71% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($6.56) to ($2.35) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.38 out of 5 starsMedical Sector449th out of 910 stocksPharmaceutical Preparations Industry205th out of 426 stocks 3.6 Analyst's Opinion Consensus RatingBenitec Biopharma has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBenitec Biopharma has only been the subject of 3 research reports in the past 90 days.Read more about Benitec Biopharma's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.71% of the outstanding shares of Benitec Biopharma have been sold short.Short Interest Ratio / Days to CoverBenitec Biopharma has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Benitec Biopharma has recently decreased by 2.21%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldBenitec Biopharma does not currently pay a dividend.Dividend GrowthBenitec Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BNTC. Previous Next 2.0 News and Social Media Coverage News SentimentBenitec Biopharma has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Benitec Biopharma this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added Benitec Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Benitec Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.30% of the stock of Benitec Biopharma is held by insiders.Percentage Held by Institutions52.19% of the stock of Benitec Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Benitec Biopharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Benitec Biopharma are expected to grow in the coming year, from ($6.56) to ($2.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Benitec Biopharma is -4.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Benitec Biopharma is -4.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBenitec Biopharma has a P/B Ratio of 75.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Benitec Biopharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…Go here now to watch my new documentary About Benitec Biopharma Stock (NASDAQ:BNTC)Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.Read More BNTC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BNTC Stock News HeadlinesSeptember 6 at 4:59 AM | americanbankingnews.comBenitec Biopharma (NASDAQ:BNTC) Shares Pass Below 50-Day Moving Average of $8.99July 23, 2024 | markets.businessinsider.comBuy Rating on Benitec Biopharma: Anticipating BB-301’s Impact on OPMD Treatment and Stock ValueSeptember 7, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…July 23, 2024 | msn.comLeerink Partners Initiates Coverage of Benitec Biopharma (BNTC) with Outperform RecommendationJuly 22, 2024 | lse.co.ukBenitec Biopharma Share Price (BNTC.US)July 19, 2024 | investing.comBenitec Biopharma Ltd ADR (BNTC)July 15, 2024 | globenewswire.comBenitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a StudyMay 20, 2024 | markets.businessinsider.comBuy Rating for Benitec Biopharma on Promising Early-Stage Clinical Data and Solid FinancialsSeptember 7, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…May 13, 2024 | finance.yahoo.comBenitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational UpdateMay 13, 2024 | investorplace.comBNTC Stock Earnings: Benitec Biopharma Misses EPS for Q3 2024May 1, 2024 | finance.yahoo.comBenitec Biopharma to Participate in the Citizens JMP Life Science ConferenceApril 18, 2024 | msn.comWhy Is Gene Therapy Developer Benitec Biopharma Stock Trading Higher On Thursday?April 18, 2024 | finanznachrichten.deBenitec Biopharma Inc.: Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a StudyApril 18, 2024 | msn.comBenitec Biopharma jumps 33% on $40M private financingApril 18, 2024 | markets.businessinsider.comWhy Benitec Biopharma Is Rising In Pre-market?April 18, 2024 | globenewswire.comBenitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a StudyApril 18, 2024 | globenewswire.comBenitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 MillionSee More Headlines Receive BNTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Benitec Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today9/07/2024Next Earnings (Estimated)9/19/2024Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BNTC CUSIPN/A CIK1808898 Webwww.benitec.com Phone510-780-0819Fax61 (0)3 9966-9923Employees20Year FoundedN/APrice Target and Rating Average Stock Price Target$19.67 High Stock Price Target$30.00 Low Stock Price Target$13.00 Potential Upside/Downside+118.0%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,560,000.00 Net MarginsN/A Pretax Margin-309,885.78% Return on Equity-175.36% Return on Assets-127.85% Debt Debt-to-Equity Ratio0.01 Current Ratio4.18 Quick Ratio4.18 Sales & Book Value Annual Sales$7,000.00 Price / Sales12,071.34 Cash FlowN/A Price / Cash FlowN/A Book Value$0.12 per share Price / Book75.17Miscellaneous Outstanding Shares9,368,000Free Float8,965,000Market Cap$84.50 million OptionableNo Data Beta0.91 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Jerel A. Banks M.D. (Age 49)Ph.D., Executive Chairman & CEO Comp: $848.07kMs. Megan Joan Boston BComm (Age 52)CA, Dip., GAICD, Executive Director Comp: $439.17kDr. Michael GrahamHead of Discovery & Founding ScientistDr. Claudia KlothSenior Vice President of ManufacturingKey CompetitorsSutro BiopharmaNASDAQ:STROVoyager TherapeuticsNASDAQ:VYGRNeoleukin TherapeuticsNASDAQ:NLTXSNDLNASDAQ:SNDLOrganogenesisNASDAQ:ORGOView All CompetitorsInstitutional OwnershipNantahala Capital Management LLCBought 841,395 shares on 8/20/2024Ownership: 8.982%Simplify Asset Management Inc.Bought 51,216 shares on 8/13/2024Ownership: 0.547%GAMMA Investing LLCBought 1,884 shares on 7/2/2024Ownership: 0.058%View All Institutional Transactions BNTC Stock Analysis - Frequently Asked Questions How have BNTC shares performed this year? Benitec Biopharma's stock was trading at $3.23 at the beginning of 2024. Since then, BNTC stock has increased by 179.3% and is now trading at $9.02. View the best growth stocks for 2024 here. When did Benitec Biopharma's stock split? Shares of Benitec Biopharma reverse split on the morning of Wednesday, July 26th 2023. The 1-17 reverse split was announced on Wednesday, July 26th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. When did Benitec Biopharma IPO? Benitec Biopharma (BNTC) raised $0 in an initial public offering on Thursday, August 6th 2015. The company issued 0 shares at a price of $0.00 per share. BMO Capital Markets and Maxim Group LLC acted as the underwriters for the IPO and Roth Capital Partners was co-manager. Who are Benitec Biopharma's major shareholders? Benitec Biopharma's top institutional shareholders include Nantahala Capital Management LLC (8.98%), Simplify Asset Management Inc. (0.55%) and GAMMA Investing LLC (0.06%). View institutional ownership trends. How do I buy shares of Benitec Biopharma? Shares of BNTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Benitec Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Benitec Biopharma investors own include Amarin (AMRN), Pfizer (PFE), Amicus Therapeutics (FOLD), Sorrento Therapeutics (SRNE), Arbutus Biopharma (ABUS), Aldeyra Therapeutics (ALDX) and AVEO Pharmaceuticals (AVEO). This page (NASDAQ:BNTC) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Benitec Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Benitec Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.